Comparison

Cagrilintide vs. Maridebart Cafraglutide

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Cagrilintide

Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.

Maridebart Cafraglutide

MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Cagrilintide	Maridebart Cafraglutide
Germany	Unapproved	Unapproved
DK	Unapproved	—
United States	Unapproved	Unapproved

Full entries

Cagrilintide

Full entry →

Maridebart Cafraglutide

Full entry →

Frequently asked questions

What is the difference between Cagrilintide and Maridebart Cafraglutide?: Cagrilintide is classified as "Metabolic", while Maridebart Cafraglutide is classified as "Metabolic". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Cagrilintide or Maridebart Cafraglutide?: The highest available evidence level is "Human RCT" for Cagrilintide and "Human RCT" for Maridebart Cafraglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Cagrilintide and Maridebart Cafraglutide in Germany and the United States?: Germany: Cagrilintide — Unapproved, Maridebart Cafraglutide — Unapproved. United States: Cagrilintide — Unapproved, Maridebart Cafraglutide — Unapproved. These are factual summaries with source and review date on the individual pages.

Country

Cagrilintide

Maridebart Cafraglutide

Germany

Unapproved

—

United States

Unapproved

Frequently asked questions

What is the difference between Cagrilintide and Maridebart Cafraglutide?

Cagrilintide is classified as "Metabolic", while Maridebart Cafraglutide is classified as "Metabolic". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Cagrilintide or Maridebart Cafraglutide?

The highest available evidence level is "Human RCT" for Cagrilintide and "Human RCT" for Maridebart Cafraglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Cagrilintide and Maridebart Cafraglutide in Germany and the United States?

Germany: Cagrilintide — Unapproved, Maridebart Cafraglutide — Unapproved. United States: Cagrilintide — Unapproved, Maridebart Cafraglutide — Unapproved. These are factual summaries with source and review date on the individual pages.